Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies
Merck & Co has put the brakes on enrolment into two Phase III trials of Keytruda in multiple myeloma to allow it to investigate more deaths in the groups receiving the anti-PD1 product.
You may also be interested in...
Safety notice for Merck's Keytruda in multiple myeloma had some notable elements – from what comes next to who delivered the message.
Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.